Home>Topics>>Shares of Lexicon Pharmaceuticals (LXRX) finished -4% today, despite its earlier announcement that that favorable data from Phase 2b clinical trials of its diabetes drug LX4211 was being presented ...
Shares of Lexicon Pharmaceuticals (LXRX) finished -4% today, despite its earlier announcement that that favorable data from Phase 2b clinical trials of its diabetes drug LX4211 was being presented ...
Shares of
Lexicon Pharmaceuticals (
LXRX ) finished -4% today, despite its earlier announcement that that favorable data from Phase 2b clinical trials of its diabetes drug LX4211 was being presented today at the American Heart Association Scientific Sessions Conference in Los Angeles. According to ...
Read the rest of this article on SeekingAlpha.com: SA Currents